Dr. Rosell has authored over 600 articles published in peer-reviewed medical and scientific journals, and he has given more than 800 presentations at medical and scientific conferences around the world. He is Editor-in-Chief of Translational Lung Cancer Research, Associate Editor for Clinical Lung Cancer, and is on the Editorial Board of respective professional journals, including Annals of Oncology, Clinical Cancer Research, and Future Oncology. He is past president of the united states of the Asociación Espanola de Investigación Sobre elevation Cancer ( ASEICA ) and past editor program of Revista de Oncología, the official publication of five Spanish oncology societies. Dr. Rosell is a penis of the International Association for the Study of Lung Cancer ( IASLC ) and was the Scientific Chair of their 2005 World Conference on Lung Cancer. He is an active penis of the Protocol Review Committee of the European Organization for Research and Treatment of Cancer ( EORTC ) and serves on the Scientific Program Sub-Committee ( non-small-cell lung cancer, metastatic ) for the annual congress of the European Medical Oncology Society ( ESMO ). He was Scientific Chair of the 1st & 2nd European Lung Cancer Congress jointly sponsored by IASLC and ESMO. He besides participated in the ASCO Scientific Programs Committee from 2002 through 2004. Terms of appointment: Jun 2019 to May 2022
Dr. Rafael Rosell is Director of the Cancer Biology and Precision Medicine Program at the Catalan Institute of Oncology, Hospital Germans Trias one Pujol ( Badalona, Barcelona, Spain ), Chief Scientific Officer, Chairman and Founder of Pangaea Biotech SL ( Barcelona ), Chief Medical Officer and President of the Dr. Rosell Oncology Institute, Quirón Dexeus University Hospital ( Barcelona ) and Founder and President of the Molecular Oncology Research Foundation ( Barcelona ). He is the Founder and Director of International Relations and Projects, Spanish Lung Cancer Group ( SLCG ), and a member of the Foundation Council and Steering Committee of the European Thoracic Oncology Platform ( ETOP ).
Dr. Rosell’s contributions to translational medical oncology, with particular emphasis on the plain of non-small-cell lung cancer with EGFR mutations, have earned him external recognition: in 2013 he was recognized by The Lancet as the highest assurance in lung cancer in Europe; he received the Raymond Bourgine Award from the International Congress on Anti-Cancer Treatment ( ICACT ) for contributions to cancer inquiry in 2012; in 2011 he was honored by the European Society of Medical Oncology ( ESMO ) with the Hamilton Fairley Award for lifetime achievements in science and clinical/laboratory research, and in 2008 the Bonnie J. Addario Lung Cancer Foundation presented him with the “ Asclepios ” Award to pioneers in research. Dr. Rosell has besides been named Professor Honoris Causa by the University of Cordoba in Argentina, Eminent Clinical Scholar in Residence by the Winship Cancer Institute, Emory University School of Medicine, Georgia, USA, and awarded the Silver Caravel by the city of Bari, Italy in recognition of his make in lung cancer. The advanced solution of Dr. Rosell’s multidisciplinary team has long focused on the design and excerpt of individualized cancer treatments based on genetic psychoanalysis and word picture of each affected role ’ randomness tumor in order to optimize outcomes to treatment. The investigations center on the word pictures of modern genes involved in the growth of cancer and resistance to targeted therapies. Among others, the group has performed groundbreaking analyses of EGFR, KRAS, and ALK angstrom well as RNA expression analysis of multiple genes such as BRCA1, AEG1, and RAP80, demonstrating significant improvements in reply to targeted treatments. In the field of lung cancer in particular they have achieved special realization for their investigations in neoadjuvant chemotherapy, demonstrating a survival profit in locally progress lung cancer, adenine well as in metastatic patients.